Increased neutralization of SARS-CoV-2 Delta variant after heterologous ChAdOx1 nCoV-19/BNT162b2 versus homologous BNT162b2 vaccination

URN to cite this document:: urn:nbn:de:bvb:355-epub-519726
DOI to cite this document:: 10.5283/epub.51972

Bauswein, Markus ; Peterhoff, David

; Plentz, Annelie ; Hiergeist, Andreas ; Wagner, Ralf ; Gessner, André ; Salzberger, Bernd ; Schmidt, Barbara

; Bauernfeind, Stilla

Preview

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 28 Mar 2022 09:43

Alternative links to fulltext:DOI Publisher Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower efficacy of this regimen. In the middle of 2021, the SARS-CoV-2 Delta variant of concern (VoC) has become predominant in many countries worldwide. Data ...